Ocrevus(ocrelizumab)
Ocrevus (ocrelizumab) is an antibody pharmaceutical. Ocrelizumab was first approved as Ocrevus on 2017-03-28. It is used to treat multiple sclerosis in the USA. It has been approved in Europe to treat multiple sclerosis. The pharmaceutical is active against B-lymphocyte antigen CD20.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| nervous system diseases | D009422 |
| immune system diseases | D007154 |
Trade Name
FDA
EMA
Ocrevus
CombinationsOcrevus zunovo
Drug Products
FDA
EMA
Reference product - 351(a)
Reference product - 351(a)
Interchangeable product - 351(k)
Interchangeable product - 351(k)
Biosimilar product - 351(k)
Biosimilar product - 351(k)
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| ocrevus | Biologic Licensing Application | 2024-11-19 |
| ocrevus zunovo | Biologic Licensing Application | 2024-11-19 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| multiple sclerosis | EFO_0003885 | D009103 | G35 |
| extravasation of diagnostic and therapeutic materials | — | D005119 | — |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
Code | Description |
|---|---|
| J2350 | Injection, ocrelizumab, 1 mg |
Clinical
Clinical Trials
132 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Multiple sclerosis | D009103 | EFO_0003885 | G35 | 3 | 7 | 37 | 16 | 53 | 114 |
| Sclerosis | D012598 | — | — | 3 | 7 | 33 | 13 | 46 | 100 |
| Relapsing-remitting multiple sclerosis | D020529 | EFO_0003929 | — | — | 5 | 20 | 7 | 10 | 42 |
| Inflammation | D007249 | MP_0001845 | — | — | — | — | 1 | 2 | 3 |
| Neuroinflammatory diseases | D000090862 | — | — | — | — | — | 1 | — | 1 |
| Syndrome | D013577 | — | — | — | — | — | 1 | — | 1 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Chronic progressive multiple sclerosis | D020528 | EFO_0003840 | — | 1 | 1 | 11 | — | 5 | 17 |
| Rheumatoid arthritis | D001172 | EFO_0000685 | M06.9 | 2 | 4 | 4 | — | — | 8 |
| Arthritis | D001168 | EFO_0005856 | M05-M14 | 2 | 4 | 4 | — | — | 8 |
| Nervous system diseases | D009422 | — | G00-G99 | 1 | — | 1 | — | 3 | 5 |
| Autoimmune diseases of the nervous system | D020274 | — | — | 1 | 1 | 1 | — | 1 | 4 |
| Autoimmune diseases | D001327 | EFO_0000540 | M30-M36 | 1 | — | 1 | — | 2 | 4 |
| Demyelinating diseases | D003711 | — | — | 1 | — | 1 | — | 2 | 4 |
| Cns demyelinating autoimmune diseases | D020278 | EFO_1000870 | G37 | 1 | — | 1 | — | 1 | 3 |
| Systemic lupus erythematosus | D008180 | EFO_0002690 | M32 | — | — | 2 | — | — | 2 |
| Neoplasm metastasis | D009362 | EFO_0009708 | — | 1 | 1 | 1 | — | — | 2 |
Show 3 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Neoplasms | D009369 | — | C80 | — | 1 | — | — | 1 | 2 |
| Fatigue | D005221 | — | R53.83 | — | 1 | — | — | 1 | 2 |
| Schizophrenia | D012559 | EFO_0000692 | F20 | 1 | 1 | — | — | — | 1 |
| Psychotic disorders | D011618 | — | F20.81 | 1 | 1 | — | — | — | 1 |
| Mental disorders | D001523 | EFO_0000677 | F91.9 | 1 | 1 | — | — | — | 1 |
| Hashimoto disease | D050031 | EFO_0003779 | E06.3 | — | 1 | — | — | — | 1 |
| Encephalitis | D004660 | — | — | — | 1 | — | — | — | 1 |
| Non-hodgkin lymphoma | D008228 | — | C85.9 | 1 | 1 | — | — | — | 1 |
| Lymphoma | D008223 | — | C85.9 | 1 | 1 | — | — | — | 1 |
| Follicular lymphoma | D008224 | — | C82 | 1 | 1 | — | — | — | 1 |
Show 1 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Immune system diseases | D007154 | — | D89.9 | 1 | — | — | — | 3 | 4 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Covid-19 | D000086382 | — | U07.1 | — | — | — | — | 3 | 3 |
| Healthy volunteers/patients | — | — | — | — | — | — | — | 3 | 3 |
| Pathologic processes | D010335 | — | — | — | — | — | — | 2 | 2 |
| Acquired immunodeficiency syndrome | D000163 | EFO_0000765 | B20 | — | — | — | — | 1 | 1 |
| Immunologic deficiency syndromes | D007153 | — | D84.9 | — | — | — | — | 1 | 1 |
| Hematologic diseases | D006402 | EFO_0005803 | D75.9 | — | — | — | — | 1 | 1 |
| Rheumatic diseases | D012216 | — | M79.0 | — | — | — | — | 1 | 1 |
| Collagen diseases | D003095 | — | — | — | — | — | — | 1 | 1 |
| Dysbiosis | D064806 | — | — | — | — | — | — | 1 | 1 |
| Patient participation | D010358 | — | — | — | — | — | — | 1 | 1 |
Show 5 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Ocrelizumab |
| INN | ocrelizumab |
| Description | Ocrelizumab, sold under the brand name Ocrevus, is a pharmaceutical drug for the treatment of multiple sclerosis (MS). It is a humanized anti-CD20 monoclonal antibody. It targets CD20 marker on B lymphocytes and hence is an immunosuppressive drug. Ocrelizumab binds to an epitope that overlaps with the epitope to which rituximab binds.
|
| Classification | Antibody |
| Drug class | monoclonal antibodies |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | — |
Identifiers
| PDB | — |
| CAS-ID | — |
| RxCUI | — |
| ChEMBL ID | CHEMBL2108041 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | DB11988 |
| UNII ID | A10SJL62JY (ChemIDplus, GSRS) |
Target
Agency Approved
MS4A1
MS4A1
Organism
Homo sapiens
Gene name
MS4A1
Gene synonyms
CD20
NCBI Gene ID
Protein name
B-lymphocyte antigen CD20
Protein synonyms
B-lymphocyte cell-surface antigen B1, B-lymphocyte surface antigen B1, Bp35, CD20, CD20 antigen, CD20 receptor, Leukocyte surface antigen Leu-16, Membrane-spanning 4-domains subfamily A member 1, membrane-spanning 4-domains, subfamily A, member 1
Uniprot ID
Mouse ortholog
Ms4a1 (12482)
B-lymphocyte antigen CD20 (P19437)
Alternate
No data
Variants
No data
Financial
Revenue by drug
$
€
£
₣
Ocrevus – Roche
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Estimated US medical usage
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 10,655 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
49,073 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use